This list includes non-CME activities funded by industry that are not programmed or accredited by the AAAAI, but that may be of interest to AAAAI members or other healthcare providers working in allergy/immunology.
For more information about any of these activities, please contact the sponsoring organizations named in the session descriptions.
To request the addition of an event to this listing, please contact Rachel McCormick, AAAAI Sponsorship Manager, at email@example.com.
Upcoming - Live Programs
Provider and Patient Utilization of Technology in a Digital Health Era: Current State and Future Opportunities
Tania Elliott, M.D. FAAAAI FACAAI
NYU Langone Health
Webcast (Presentation + Video):
Click (Chrome recommended): https://onlinexperiences.com/Launch/Event/ShowKey=201680
“Standard Registration” should be used for external participants which just requires name and email.
You can access the webcast via your computer or mobile device by clicking the link above. For technical support, please email VIP.Webcast@tevapharm.com.
Sponsored by Teva Pharmaceuticals
The Future of Food Allergy: Novel Treatment Options on the Horizon
This activity is supported by an educational grant from Genentech, a member of the Roche Group and provided by Physicians’ Education Resource.
Food allergy continues to be of concern due increasing prevalence and limited therapeutic options, prompting the need for further research into prevention and treatment. This program will take a deeper dive into the impact of food allergy, current management strategies for patients and new and emerging treatment options that can potentially impact the future of care. Cases will be presented to emphasize clinical pearls that can be applied to learners’ practice.
Expert Perspectives on Managing Moderate-to-Severe Atopic Dermatitis in Pediatric and Adult Patients
This activity is provided by Med Learning Group.
This activity is co-provided by Ultimate Medical Academy/Complete Conference Management (CCM).
This activity is supported by an education grant from Sanofi Genzyme and Regeneron Pharmaceuticals, Inc.
This enduring virtual activity targets healthcare gaps related to the diagnosis, treatment, and individualized management of AD, impacting outcomes through identifying burdens affecting quality of life, assessing disease severity when considering topical vs systemic intervention, and utilizing strategies in shared decision-making when determining guideline-based care.
- By addressing these gaps, you can assess whether your approach to AD management through utilization of current treatment guidelines, individualization of care through the “step-up care” approach and strategies for disease severity assessment – can be modified to help close these gaps.
- Expert discussion will guide you in analyzing and identifying challenges to AD management, the relationship with Type 2 allergic co-morbid diseases, and how to navigate proactive vs reactive control.
- You will also be immersed in interactive, animated simulation case studies to memorably highlight key points related to assessment of, and treatment decisions for AD.
Peter Lio, MD
Mark Boguniewicz, MD